Supernus Pharmaceuticals

Quarterly Financials

Values in thousands2026-03-312025-12-312025-09-302025-06-30
Revenue
$207,705
$211,572
$192,103
$165,453
Gross Profit
184,314
188,565
173,138
148,626
EBITDA
18,703
26,672
-35,425
33,499
EBIT
-7,441
1,656
-60,231
12,141
Net Income
-2,293
-4,105
-45,117
22,499
Net Change In Cash
207,705
211,572
192,103
165,453
Free Cash Flow
66,524
19,434
-61,793
58,080
Cash
184,869
128,448
151,371
144,711
Basic Shares
57,647
57,344
56,552
56,643

Annual Financials

Values in thousands2025-12-312024-12-312023-12-312022-12-31
Revenue
$718,952
$661,817
$607,521
$667,238
Gross Profit
644,390
583,911
523,742
580,017
EBITDA
42,533
178,284
90,043
153,356
EBIT
-49,030
97,870
5,184
67,813
Net Income
-38,550
73,865
1,316
60,711
Net Change In Cash
718,952
661,817
607,521
667,238
Cost of Revenue
-110,314
Free Cash Flow
45,993
171,226
110,534
116,414
Cash
128,448
69,331
75,054
93,120
Basic Shares
56,451
55,959
55,506
61,679

Earnings Calls

QuarterEPS
2026-03-31
$0.21
2025-12-31
$0.88
2025-09-30
$0.61
2025-06-30
$0.91